New Lows: Catamaran Corp (NASDAQ:CTRX), Lexicon Pharmaceuticals (NASDAQ:LXRX), Uranium Energy (NYSEMKT:UEC), VIVUS, Inc. (NASDAQ:VVUS)

Jefferies Group cut their price target on shares of Catamaran Corp (NASDAQ:CTRX) from C$70.00 to C$58.00 in a research note issued on Monday, Analyst Ratings Network reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target indicates a potential upside of 15.70% from the company’s current price. Catamaran Corp (USA) (NASDAQ:CTRX) shares after opening at $43.93 moved to $44.19 on last trade day and at the end of the day closed at $42.64. Company price to sales ratio in past twelve months was calculated as 0.60 and price to cash ratio as 22.73. Catamaran Corp (USA) (NASDAQ:CTRX) showed a negative weekly performance of -4.12%.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that Lexicon management will present at the Needham Healthcare Conference on Tuesday, April 8, 2014 at 9:20 AM EDT in New York City. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares fell -5.92% in last trading session and ended the day on $1.59. LXRX return on equity ratio is recorded as -51.30% and its return on assets is -33.50%. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) yearly performance is -27.40%.

On March 13, 2014, Uranium Energy Corp. (NYSEMKT:UEC) entered into an amended and restated credit agreement (the “Amended and Restated Credit Agreement”) by and among (i) the Company, (ii) certain of the Company’s U.S. subsidiaries, specifically, South Texas Mining Venture L.L.P.Uranium Energy Corp. (NYSEMKT:UEC) shares moved down -2.34% in last trading session and was closed at $1.25, while trading in range of $1.25 – $1.35. Uranium Energy Corp. (NYSEMKT:UEC) year to date (YTD) performance is -37.50%.

Shares of VIVUS (NASDAQ:VVUS), which has developed an anti-obesity drug, are declining after research firm Piper Jaffray downgraded the stock in a note to investors. VIVUS, Inc. (NASDAQ:VVUS) weekly performance is -5.24%. On last trading day company shares ended up $5.42. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is -16.25%. Analysts mean target price for the company is $9.00.